Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation

Rapamycin‐related mTOR inhibitors (rapalogs) possess immunosuppressive and antiproliferative properties. Their mechanism of action makes them attractive therapies for several disease states but also potentiates adverse effects associated with these drugs. The oral mTOR inhibitor everolimus was recen...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2015-04, Vol.55 (4), p.368-376
Main Authors: Somers, Michael J.G., Paul, Elahna
Format: Article
Language:English
Subjects:
angiomyolipoma
everolimus
Humans
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Kidney Transplantation
mTOR inhibition
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
rapalog
renal transplantation
safety
sirolimus
Sirolimus - adverse effects
Sirolimus - analogs & derivatives
Sirolimus - therapeutic use
TOR Serine-Threonine Kinases - antagonists & inhibitors
Transplants & implants
Tuberous Sclerosis - drug therapy
tuberous sclerosis complex
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rapamycin‐related mTOR inhibitors (rapalogs) possess immunosuppressive and antiproliferative properties. Their mechanism of action makes them attractive therapies for several disease states but also potentiates adverse effects associated with these drugs. The oral mTOR inhibitor everolimus was recently approved for the treatment of tuberous sclerosis complex (TSC)‐associated renal angiomyolipoma. As clinical use of rapalogs for the treatment of TSC increases, nephrologists and urologists who treat both children and adults with renal masses, as well as internists and geneticists with an interest in renal disease, should be aware of their safety profiles. This review presents the clinical experience of rapamycin‐related mTOR inhibitors in patients with TSC and summarizes their toxicity profiles in renal transplant and TSC populations. Increased usage of rapalogs in a variety of patient populations demands vigilant monitoring of their safety profiles and rigorous differentiation between disease‐specific and drug‐specific toxicities.
ISSN:0091-2700
1552-4604
DOI:10.1002/jcph.428